24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical trial NCT05677451 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05677451
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-11
- Primary completion
- 2026-11-03
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.